ArticleRadiation oncology (London, England)2017
Improved plan quality with automated radiotherapy planning for whole brain with hippocampus sparing: a comparison to the RTOG 0933 trial.
Article in Radiation oncology (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Reference-Free large language model agents for physician-guided radiotherapy treatment planning.Medical physics · 2026Article
- An automated planning optimization framework for cervical intensity-modulated radiation therapy using voxel dose prediction and adaptive parameter tuning.Physics and imaging in radiation oncology · 2026Article
- Semi-automated hippocampal avoidance whole-brain radiotherapy planning.Journal of applied clinical medical physics · 2025Article
- An innovative hippocampal-sparing whole-brain radiotherapy planning approach via the Halcyon system: achieving lower hippocampal doses.Frontiers in oncology · 2025Article
- Article
- A simplified non-coplanar volumetric modulated arc therapy for the whole brain radiotherapy with hippocampus avoidance.Frontiers in oncology · 2023Article
- Review
- Application of piecewise VMAT technique to whole-brain radiotherapy with simultaneous integrated boost for multiple metastases.Radiation oncology (London, England) · 2022Article
- Artificial Intelligence in Radiation Therapy.IEEE transactions on radiation and plasma medical sciences · 2022Article
- Review
- Evaluation of Automated Treatment Planning and Organ Dose Prediction for Lung Stereotactic Body Radiotherapy.Cureus · 2021Article
- Optimization of collimator angles in dual-arc volumetric modulated arc therapy planning for whole-brain radiotherapy with hippocampus and inner ear sparing.Scientific reports · 2021Article
- Support Vector Machine Model Predicts Dose for Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer.Frontiers in oncology · 2021Article
- Article
- Automated contouring and planning pipeline for hippocampal-avoidant whole-brain radiotherapy.Radiation oncology (London, England) · 2020Article
- [Role of hippocampal avoidance during therapeutic whole-brain radiotherapy].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Automated Hypofractionated IMRT treatment planning for early-stage breast Cancer.Radiation oncology (London, England) · 2020Article
- Individualized automated planning for dose bath reduction in robotic radiosurgery for benign tumors.PloS one · 2019Article
- Automation in intensity modulated radiotherapy treatment planning-a review of recent innovations.The British journal of radiology · 2018Review
- Planning comparison of five automated treatment planning solutions for locally advanced head and neck cancer.Radiation oncology (London, England) · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhole-brain radiation therapy (WBRT) with hippocampus sparing (HS) has been investigated by the radiation oncology working group (RTOG) 0933 trial for patients with multiple brain metastases. They showed a decrease of adverse neurocognitive effects with HS WBRT compared to WBRT alone. With the development of automated treatment planning system (aTPS) in the last years, a standardization of the plan quality at a high level was achieved. The goal of this study was to evaluate the feasibility of using an aTPS for the treatment of HS WBRT and see if the RTOG 0933 dose constraints could be achieved and improved.
methodsTen consecutive patients treated with HS WBRT were enrolled in this study. 10 × 3 Gy was prescribed according to the RTOG 0933 protocol to 92% of the target volume (whole-brain excluding the hippocampus expanded by 5 mm in 3-dimensions). In contrast to RTOG 0933, the maximum allowed point dose to normal brain was significantly lowered and restricted to 36.5 Gy. All patients were planned with volumetric modulated arc therapy (VMAT) technique using four arcs. Plans were optimized using Auto-Planning (AP) (Philips Radiation Oncology Systems) with one single AP template and optimization.
resultsAll the constraints from the RTOG 0933 trial were achieved. A significant improvement for the maximal dose to 2% of the brain with a reduction of 4 Gy was achieved (33.5 Gy vs. RTOG 37.5 Gy) and the minimum hippocampus dose was reduced by 10% (8.1 Gy vs. RTOG 9 Gy). A steep dose gradient around the hippocampus was achieved with a mean dose of 27.3 Gy at a distance between 0.5 cm and 1 cm from the hippocampus. The effective working time to optimize a plan was kept below 6'.
conclusionAutomated treatment planning for HS WBRT was able to fulfil all the recommendations from the RTOG 0933 study while significantly improving dose homogeneity and decreasing unnecessary hot spot in the normal brain. With this approach, a standardization of plan quality was achieved and the effective time required for plan optimization was minimized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.